Determine the current status of the musculoskeletal disease (MSD) treatments and assess the growth potential of this area over a 5-year period from 2009 to 2014.
Highlights
* The global market for musculoskeletal disease is currently approaching $45 billion. The overall 5-year compound annual growth rate (CAGR) is forecasted to be about 5%, bringing the total market to m…
 |
Therapeutics and Biomaterials for Musculoskeletal Disease: Global Markets
|
|
|
Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets
An overview of the current state of drug discovery in the ubiquitin proteasome research field, existing products on the market, and detailed analysis of the competitive environments, including new potential markets for current research projects. Includes forecasts through 2015.
Highlights * There is only one approved UPS product on the market, Velcade, a proteasome inhib… |
|
|
Biological Therapies for Cancer: Technologies and Global Markets
This report provides a detailed overview and thorough analysis of the present and future global market for cancer biotherapeutics
Highlights : *Coverage of biological products in development, in clinical trials, currently marketed, and late-stage-development biologic cancer products *Analysis of market trends, citing data for 2008, estimates for 2009, and projection… |
 |
How is Beckman these days in the tools for research space? In particluar assay k…
How is beckman these days in the tools for research space? In particluar assay kits and robtoics? Is this an area of growth for them or are they loosing market share in recent years?
|
 |
Multiple products but low price?
Ignoring the Phase II failure today, can someone elaborate as to why the market cap of this compnay is so low given they have multiple products?
|
 |
Will Abbott be a re-bound stock given low level and P/E of 14ish?
Will Abbott be a re-bound stock given the low price level it has reached over the recent year or so and P/E of 14ish? It really has not been part of the recent rally in the markets..
|
 |
Is it a good time to get into Sequenome looking for a rebound?
Is it a good time to get into Sequenome looking for a rebound after the CEO removal? The other consideration is where are they going long term? It seems they are loosing around $20M a qtr and that only gives them a runway of 9 mnths or so before cash becmes an issue.
|
 |
Is Luminex a likely acquisition target?
Is Luminex a likely acquisition given the many systems it has across so many orgnizations and it being listed as Forbes as one of the 25 Fastest-Growing Technology Companies in America. The company seems to struggle making it to the big time on its own yet at the same time draws a great deal of attention in the sector?
|
 |
Anyone have thoughts on if Celera has a timeline to profitability?
Anyone know if Celera has a timeline to profitability and the liklihood that will occur? I do not yet hold the stock.
|
|
|
Progen's cash position?
In looking at Progen's announcement I cannot work out their current cash position. Can anyone help on that?
|